-
-
-
-
-
-
-
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant R
-
-
-
-
-
-
-
Synthetic Biologics (SYN) Announces 1:10 Reverse Stock Split
-
-
-
-
-
-
-
Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & C
-
-
-
-
-
-
-
Synthetic Biologics Completes Acquisition of VCN Biosciences
-
-
-
-
-
-
-
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
-
-
-
-
-
-
-
Pre-Open Movers 05/11: (SGMO) (SYMX) (PEGA) Higher; (NH) (SNAP) (MNKD) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Stock Movers 05/16: (NSPH) (ANAC) (TPUB) Higher; (BBEP) (ADRO) (TRVN) Lower (mor
-
1,157,989 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

